Assembly Biosciences

24 articles with Assembly Biosciences

• Safety and Antiviral Activity of Assembly Biosciences’ First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLD

  10/16/2019

  Phase 2a studies of ABI-H0731 + nucleos(t)ide analogs (Nrtl) in HBeAg+ patients show faster and deeper declines in HBV DNA and RNA with combination than Nrtl alone, as well as subsequent declines in the surrogate markers of cccDNA with long-term treatment

• 

  BioSpace Movers and Shakers, Aug. 9

  8/9/2019

  Biopharma companies strengthen their senior leadership teams and boards of directors.
• 

  Top 10 Cities in the U.S. for the Job Market

  1/15/2019

  New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.

• Assembly Biosciences Announces Oral Presentation at 2018 AASLD

  10/2/2018

  Assembly Biosciences, Inc. today announced that the company will have an oral presentation of the full data set from the Phase 1b study of ABI-H0731 at the upcoming American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), being held November 9-13 in San Francisco.

• Assembly Biosciences Selects Next-Generation CpAM Candidate For Advancement Into Clinical Development

  9/25/2017

• Assembly Biosciences Announces The Closing And Early Termination Of Hart-Scott-Rodino Waiting Period For License Of Microbiome Gastrointestinal Development Programs To Allergan

  2/21/2017

• Assembly Biosciences Announces Successful Completion Of ABI-H0731 Phase Ia Trial And Upcoming Conference Presentations

  2/16/2017

• Allergan Enters Into Licensing Agreement With Assembly Biosciences To Obtain Worldwide Rights To Microbiome Gastrointestinal Development Programs

  1/9/2017

• Assembly Biosciences Initiates Phase I Clinical Program Of ABI-H0731 For Treatment Of Chronic Hepatitis B Virus Infection

  11/9/2016

• Assembly Biosciences Announces Key Additions To Microbiome Team

  9/28/2016

• Assembly Biosciences Announces Participation In HBV Scientific Meetings In China And South Korea

  9/21/2016

• Assembly Biosciences To Present At The Jefferies 2016 Global Healthcare Conference

  6/1/2016

• Assembly Biosciences To Present Data At The International Liver Congress 2016 That Supports Advancing Its CpAM Candidates Into HBV Clinical Trials

  4/13/2016

• Assembly Biosciences To Present Data On New Series Of HBV Core Protein Allosteric Modifiers At The International Liver Congress™ 2016

  3/30/2016

• Assembly Biosciences Expands Senior Leadership Team

  1/11/2016

• Assembly Biosciences Appoints Biotech Veteran Alan J. Lewis To Board Of Directors

  12/21/2015

• Assembly Biosciences To Present At Jefferies Microbiome Summit

  12/16/2015

• Clinical Study Shows Assembly Biosciences' Oral Gemicel Technology Can Achieve Targeted Delivery To The Lower GI Tract For Microbiome And Other Applications

  12/9/2015

• Assembly Biosciences To Describe Improved Methods For HBV Drug Development At Major International Meeting

  10/6/2015

• Assembly Biosciences Discusses Mechanism Of Action Of Its HBV Antiviral Program At 2nd ANRS HBV Cure Workshop

  5/19/2015